NEW YORK, March 12, 2018 -- City National Bank, America’s Premier Private and Business Bank®, announced today that Matthew Peron has joined its investment management division, City National Rochdale, as its new chief investment officer (CIO). Peron will lead investment strategy at the asset management firm, which manages $37 billion in assets.
As CIO, Peron will be responsible for providing investment management leadership to City National Rochdale. Drawing upon nearly 30 years of extensive financial services experience, he will strengthen City National Rochdale’s capabilities with the goal of helping clients achieve their investment goals. He will provide thought leadership and help to shape the firm’s investment philosophy, processes and policies in order to drive future growth. He will manage all equity and fixed-income teams, lead the firm’s asset allocation committee, and develop research and strategies to support asset allocation decisions.
“Matt is a talented and distinguished expert with a strong track record of developing and leading successful investment strategies,” said Garrett D’Alessandro, chief executive officer at City National Rochdale in New York. “He will strengthen our ability to deliver high-quality investment management through strategies that are rigorously designed, based on the best research and disciplined in their implementation.”
Prior to joining City National, Peron served as executive vice president and managing director of Global Equity at Northern Trust in Chicago. He earned a master’s degree in business administration from the University of Chicago and a bachelor’s degree from Swarthmore College.
“City National Rochdale has a collaborative, client-first culture and a track record of excellence and innovation,” said Peron, who will be based primarily in the firm’s New York office. “The firm has a lot of room to grow and succeed, and I am looking forward to working with the team as we further establish City National Rochdale as a leader in investment management.”
For an image of Peron, go to: https://www.cnb.com/PublishingImages/Peron_Matthew.jpg
About City National Rochdale
For more than 30 years, City National Rochdale has specialized in intelligently personalized portfolio management for high-net worth individuals, families and institutions, and provides clients with service that relates all investment decisions to each client’s personal benchmark. City National Rochdale, headquartered in Beverly Hills and New York City with offices around the country, currently manages $37 billion in assets as of January 31, 2018, and is a wholly owned subsidiary of City National Bank.
For more information, visit www.cnr.com.
About City National Bank
With $48.7 billion in assets, City National Bank provides banking, investment and trust services through 72 offices, including 19 full-service regional centers, in Southern California, the San Francisco Bay Area, Nevada, New York City, Nashville, Atlanta, Minneapolis and Washington, D.C. In addition, the company and its investment affiliates manage or administer $64.9 billion in client investment assets.
City National is a subsidiary of Royal Bank of Canada (RBC), one of North America’s leading diversified financial services companies. RBC serves more than 16 million personal, business, public sector and institutional clients through offices in Canada, the United States and 34 other countries.
For more information about City National, visit the company’s website at cnb.com.
DISCLOSURES:
The information presented does not involve the rendering of personalized investment, financial, legal or tax advice. This presentation is not an offer to buy or sell, or a solicitation of any offer to buy or sell, any of the securities mentioned herein.
Certain statements contained herein may constitute projections, forecasts and other forward-looking statements, which do not reflect actual results and are based primarily upon a hypothetical set of assumptions applied to certain historical financial information. Certain information has been provided by third-party sources, and although believed to be reliable, it has not been independently verified, and its accuracy or completeness cannot be guaranteed.
Any opinions, projections, forecasts and forward-looking statements presented herein are valid as of the date of this document and are subject to change.
All investing is subject to risk, including the possible loss of the money you invest. Past performance is no guarantee of future results.
Investment management services provided by City National Bank through its wholly owned subsidiary City National Rochdale, LLC, a registered investment advisor.
Non-deposit investment products are not FDIC insured, are not bank guaranteed and may lose value.
Media Contact:
Debora Vrana, City National Bank, 213.673.7631
[email protected]


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Anta Sports Expands Global Footprint With Strategic Puma Stake
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



